FLT3 and acute myeloid leukemia: Unfortunately, we still lack prospective randomized trials evaluating the optimal post-remission therapeutic strategy in FLT3-mutated AML, also taking into consideration the FLT3-ITD allelic ratio, co-mutation combinations, and—more recently—the use of FLT3 inhibitors during treatment.